Mental health changes after 4 months of weight loss treatment with the glucagon‐like peptide‐1 analogue liraglutide 3.0 mg
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70393 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Susanne Kuckuck und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Liraglutide, Weight Loss, Obesity, Mental Health. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Dutch Research Council and the Dutch Ministry of Education, Culture and Science.
Abstract (Originalsprache)
Objective
This observational study examined changes in mental health and wellbeing after 4‐months liraglutide 3.0 mg treatment in patients with obesity and explored associations with weight loss.
Methods
We included 98 patients with obesity treated with liraglutide 3.0 mg. The Hospital Anxiety and Depression Scale (HADS: total score 0–42; depression/anxiety subscales 0–21), OBESI‐Q psychological wellbeing (0–100) and anthropometrics were assessed at baseline and 4‐month follow‐up. Analyses included the full sample and subgroups with poor versus good baseline mental health.
Results
Body weight decreased after 4 months (−5.8%, p < 0.001). HADS total, depression, and (in trend) anxiety scores slightly decreased (−1.7 [95% confidence interval [CI] −3.2; −0.1, p < 0.05]; −1.0 [95% CI: −1.9; −0.1, p < 0.05] and −0.7 [95% CI: −1.5; 0.1, p = 0.095]). OBESI‐Q psychological wellbeing scores increased (4.3 [95% CI: 0.8; 7.8, p < 0.05]). Mental health improvements occurred mainly in patients with poor baseline mental health. Weight loss occurred regardless of initial mental health. Anthropometrics changes were associated with changes in mental health and psychological wellbeing either significantly or in trend.
Conclusion
Liraglutide treatment was associated with weight loss without adverse mental health changes. Mental health benefits may be seen especially in those initially impaired. Weight loss was irrespective of baseline mental health status, suggesting liraglutide weight loss treatment effectiveness even in the presence of impaired mental health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Obesity Center CGG, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Department of Biostatics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Department of Psychiatry, Amsterdam Neuroscience and Amsterdam Public Health, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
ORCID-Profile: Mariëtte R Boon, Elisabeth F C van Rossum
Förderung
- Dutch Research Council and the Dutch Ministry of Education, Culture and Science
Zitieren
APA
Kuckuck, S., van Gerwen, N., Oosterman, J. E., Savas, M., Kavousi, M., Penninx, B. W. J. H., Boon, M. R., & van Rossum, E. F. C. (2026). Mental health changes after 4 months of weight loss treatment with the glucagon‐like peptide‐1 analogue liraglutide 3.0 mg. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70393
Vancouver
Kuckuck S, van Gerwen N, Oosterman JE, Savas M, Kavousi M, Penninx BWJH, et al. Mental health changes after 4 months of weight loss treatment with the glucagon‐like peptide‐1 analogue liraglutide 3.0 mg. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70393
BibTeX
@article{Kuckuck2026,
author = {Kuckuck, Susanne and van Gerwen, Nina and Oosterman, Johanneke E and Savas, Mesut and Kavousi, Maryam and Penninx, Brenda W J H and Boon, Mariëtte R and van Rossum, Elisabeth F C},
title = {Mental health changes after 4 months of weight loss treatment with the glucagon‐like peptide‐1 analogue liraglutide 3.0 mg},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70393}
}
EUVIMED